Category Archives: General Cynicism

Big PHarma and Families USA–A Unholy Alliance

Politico reports Families USA and PHarma working together on reforming Medicaid.

Medicynical note: Medicaid reform is probably a good idea but should not take the place of a more fundamental review of health care policy, with particular emphasis on cost containment.

PHarma has one and only one goal. To promote and protect the profits of pharmaceutical companies. That’s their responsibility as the lobbying arm of the industry. It’s as close to a fiduciary responsibility as there is. They oppose a public insurance plan, oppose comparison studies of efficacy, oppose negotiation of prices for Medicare part D, oppose patent reform and by inference oppose cost containment if it effects company profits

PHarma doesn’t want reform they want surrender to their goals and objectives.

Powered by Zoundry Raven

Lilly Gross Profit of 84%– Show No Mercy

Lilly announced an earnings increase of 23% over last year’s results.

“Lilly, which reiterated its 2009 earnings target, is among a slew of pharmaceutical firms that have raised some prices aggressively.” in recent months even as government and private insurers struggle to rein in health care costs.”

“Gross margin rose to 83.8% from 76.9% (Medicynical emphasis) as the stronger dollar eased international sales costs. Total sales costs slumped 27%.”

Investopedia defines gross margin as “A financial metric used to assess a firm’s financial health by revealing the proportion of money left over from revenues after accounting for the cost of goods sold.Gross Profit = Revenue − Cost of Goods Sold.”

Medicynical Note: Big profits, seemingly defying the pull of gravity (the current financial crisis). It would seem to me that 86% margin is excessive. But then what is excess profits in a capitalistic society? The larger question is can we afford this level of profits in health care? How to limit? Should we limit?

New advances that we cannot afford have the same impact as trees falling in the woods.

Powered by Zoundry Raven

BIG PHarma–price increases over twice the rate of inflation!!

AARP is not the most reliable unbiased source, given it’s Medicare D insurance business. But it notes:

“manufacturer prices for widely used brand name prescription drugs jumped by nearly nine percent (Medicynical emphasis) in 2008, marking the largest average annual increase in six years and far exceeding the general inflation rate of just 3.8 percent.”

Big Pharma just can’t resist.

Powered by Zoundry Raven

Cost Containment

The Columbia Journalism Review has an interview with Medicare expert Marilyn Moon, vice president of the American Institutes for Research, and a former trustee of the Medicare system:

“No one has really solved the cost containment problem in this country, but Medicare has done as well as any other effort. Rising costs are not a Medicare problem but a health system problem. We have not been willing to make sure we are getting value for the dollars we spend. We have not been spending money wisely. Until everyone-providers, patients, and others who have a stake in manufacturing drugs, devices, new treatments-becomes realistic in what the system will bear, we are not going to see any reduction in the growth of health care spending.”

Medicynical Note: What will get their attention? Patent reform? The threat of a single provider system? Increased regulation of insurers? More out of pocket expenses (HSA’s)? What’s clear is something needs to be done. LBJ had an approach: “Son, it’s really simple. You grab ’em firmly by the balls. Their hearts and minds will follow.”

Powered by Zoundry Raven

Graphics on Why Health Reform

From the Baucus plan:

“The U.S. is the only developed country without health coverage for all of its citizens.3 An estimated 45.7 million Americans, or 15.3 percent of the population, lacked health insurance in 2007 – up from 38.4 million in 2000.4 Those without health coverage generally experience poorer health and worse health outcomes than those who are insured. Twentythree percent forgo necessary care every year due to cost. And a number of studies show that the uninsured are less likely to receive preventive care or even care for traumatic injuries, heart attacks, and chronic diseases. The Urban Institute reports that 22,000 uninsured adults die prematurely each year as a direct result of lacking access to care.”

“Even before the current economic crisis, working families and individuals found their health care in jeopardy as the cost of employer-sponsored coverage rose beyond the means of businesses – particularly small businesses – and workers alike. As Figure 1.2 shows, health insurance premiums have increased faster than wages and inflation for most years between 1988 and 2007. Premiums have increased 117 percent for families and individuals and 119 percent for employers between 1999 and 2008.”

“In a study of global health care systems, journalist and author T.R. Reid found startling cost differences with the U.S. In Japan’s largely private system, the cost for magnetic resonance imaging (MRI) is less than $100, compared to $1,200 in the U.S. In Switzerland, home to profitable insurance companies and influential pharmaceutical companies, administrative costs represent 5.5 percent of total costs, compared to about 22 percent for coverage purchased in the private insurance market in the U.S.31 While there must be a uniquely American answer to the question of containing health care costs, other countries demonstrate the possibility of success.”

Powered by Zoundry Raven

Arguing Against Comparison Studies– Anti-intellectualism or Greed?

It’s hard to believe that one can argue against learning what works. But that’s exactly the position of drug and device makers in this article in the Wall Street Journal. It’s hard to believe that this is an issue.

At a minimum such studies will guide physicians in explaining benefits of, risks from and alternatives to various treatments. Comparisons will also help with analyzing the cost-effectiveness of various interventions. Whether insurers will use such data to decide what they will and will not cover is an open question.

My question is when new drugs are prohibitively expensive and have minimal effect on disease course, should insurers pay for their use? Should doctors recommend their use? Should there be limits on “choice” in health care when someone else is paying?

Powered by Zoundry Raven

Why Insurers Need Regulation–Because of the Money!

An example of the problems with “free” markets in health care–lack of coverage for expensive oral medications used in cancer care. For a number of years, oral medications have been increasingly used in cancer treatment . From Xeloda (oral 5 FU) to Gleevac (imitinab) expensive oral agents have become an integrated into treatment.

Gleevac (imitinab) one of the early targeted drugs (tyrosine kinase inhibitor in Chronic Myelogenous Leukemia) costs anywhere from $40,000/year to $90,000/year depending on dose and indication. Over a lifetime this drug becomes more expensive than most homes. Average families (Median U.S. income about $50,000/year) cannot afford such expense unless insurance provides coverage or they receive free drugs from the company.

Medicare took care of this problem with it’s Part D drug coverage. The issue with Medicare is the donut hole in coverage which requires a yearly $3,000 payment and the 5% copay after the donut payment is completed. In some cases this 5% payment can be considerable as noted in the article.

Most private insurers have lagged in providing this coverage. Oregon has now required insurers to provide equal coverage for IV and oral chemotherapy medication. The rest need more adult supervision.

Another issue is the price demanded by pharmaceutical companies. You and I grant these companies monopoly status for a generation (a patent). This is an industry/government sanctioned imfringement on free “markets”This restraint on open competition is granted theoretically to “encourage development of innovative agents.”

However, drugs priced at more than the yearly income of citizens have become simply unaffordable–by individuals as well as insurers. In other industrialized nations these same medications are priced significantly less. These countries negotiate and otherwise review new drugs and require more appropriate pricing. We need patent reform here as well.

Powered by Zoundry Raven

The Challenge of Cost Containment

Most people believe we spend too much on health care. From the April 7 Annals of Internal Medicine:

“The United States spends more than any other country on medical care. In 2006, U.S. health care spending was $2.1 trillion, or 16% of our gross domestic product. At the same time, more than 45 million Americans lack health insurance and our health outcomes (life expectancy, infant mortality, and mortality amenable to health care) are mediocre compared with other rich democracies. We spend too much for what we get.”

The Obama administration’s approach to control costs focus’s on “improving medical practice and health outcomes and changing the structure of the health insurance marketplace.”

In the category of improving medical practice Obama appears want to improve prevention services, promote health information technology (HIT), better manage chronic diseases, offer payment reforms that would pay providers on the basis of outcomes, and compare effectiveness different approaches. Yet as the article notes none of these interventions offer significant savings though they may improve outcomes and the process of health care.

Some savings are achievable through insurance reform:

“Insurance regulation can reduce costs (in principle) by limiting the resources that private insurers put into avoiding sales to less healthy customers and charging them much higher premiums. By prohibiting such medical underwriting and by requiring insurers to accept applicants regardless of health status, President Obama’s health reform approach could produce some administrative savings. An effective insurance exchange (a new agency that would offer Americans a choice of health insurance plans while also regulating insurers) can lower the high administrative costs that are typical in the current individual and small group insurance markets. In addition, the Obama platform proposed more direct limits on insurance overhead. It promised to “force insurers to pay out a reasonable share of their premiums for patient care instead of keeping exorbitant amounts for profits and administration.”

Medicynical note: This reform saves money by encouraging increased efficiency while ensuring equitable coverage.

The Annals then goes on to explore what works in other settings and concludes:

“If the United States is to control health care costs, it will have to follow the lead of other industrialized nations and embrace price restraint, spending targets, and insurance regulation. Such credible cost controls are, in the language of politics, a tough sell because they threaten the medical industry’s income. The illusion of painless savings, however, confuses our national debate on health reform and makes the acceptance of cost control’s realities all the more difficult.”

Medicynical note: We have a medical industrial complex as well organized and resistant to change as the military industrial complex that Eisenhower warned about. To achieve cost savings will require altering our cost structure and profit assumptions that have been increasingly entrenched over the past 50 years.

This article points out some false assumptions and the difficulties ahead.

Powered by Zoundry Raven

Provenge–Poster child for comparison studies

Lots of news on Provenge, (also in Bloomberg) a drug being tested in patients with hormone refractory advanced prostate cancer. Dandreon, the manufacturer has highlighted results in an incomplete study, perhaps jeopardizing it’s integrity.

“Provenge appeared to cut patients’ death rates by 20% compared with a placebo treatment, the company said. The release also contained statistical details that made good results seem likely when final results are released in April.”

What is a 20% improvement? Is it 1 month, two months or a year?

Compared with a placebo? Sugar pills and such? I would hope it would offer some benefit.

It’s good to see progress in this disease, but this is premature reporting more for the benefit of financial types than medical. This new drug will undoubtedly cost thousands/ month. At some point, comparison with and combination with the current best therapies will allow a more reasonable assessment of efficacy and cost/effectiveness.

Powered by Zoundry Raven

Health Care for all–errr, for all who can afford it

Employer based insurance is failing. It doesn’t work for employers, many of whom can’t afford to provide coverage, particularly those with lower income employees. And it doesn’t work for the employee who either has no insurance or has to spend a significant proportion of income to buy coverage.

McKinsey Quarterly notes that :

“In 2005, employer-paid health benefits covered 22 percent of households in the bottom-income group, contrasted with 56 percent of the lower-middle, 81 percent of the upper-middle, and 89 percent of the top income group”

To understand the magnitude of costs relative to income:

You will note for those earning under $27,000 dollars/year, health insurance costs are in the range of 20% of income, while for those earning over 130,000/year it’s just 3.3%.

Meanwhile Ramesh Ponnunu (of the National Review) in an OP-ED, advocated a move away from employer provided health insurance. Medicynical note: Can’t argue with that as I believe the employer based insurance system has failed.

His approach, however, would allow employers to drop health insurance and provide a tax credit to the employee to buy insurance on the private, individual market. He argued that this will bring market forces to bear on health care costs.

His plan discounts the high cost of insuring those with illness, that of course is the whole point of health insurance saying vaguely that they would be provided subsidies to buy coverage. He also neglects the issue of below average income people (after all that is 50% of the population) and the high cost of health insurance, relative to income.

His tax credits, as I understand it, will provide a decrease in the amount of taxes paid. But it won’t provide relief for a significant part of our population. For example, families and individuals with $27,000 or less income have no tax liability (see here).

We can do better than this.

Powered by Zoundry Raven